Results 211 to 220 of about 28,693,335 (281)

Operationalizing BioSSbD: A safe‐and‐sustainable‐by‐design framework for biorefineries

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Biorefineries are central to the transition toward a circular bioeconomy; however, their increasing scale and technological heterogeneity, and the integration of biological, chemical, and thermochemical processes introduce complex challenges related to safety, sustainability, and operational reliability. Existing Safe‐and‐Sustainable‐by‐Design
Fernando Ramonet
wiley   +1 more source

Interventional treatment options for elderly patients with mitral regurgitation. [PDF]

Future Cardiol
Felbel D, Rottbauer W, Keßler M.
europepmc   +1 more source

A system dynamics‐based framework for bioenergy planning in sub‐Saharan Africa: integrating circular bioeconomy and Fourth Industrial Revolution technologies

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Energy scarcity remains a persistent challenge in sub‐Saharan Africa (SSA), where limited access to reliable, affordable, and clean energy constrains socioeconomic development. Biomass resources, including agricultural residues, forest waste, and waste from other biological sources, are widely available, but their use for modern energy ...
Joseph O. Dirisu, Thywill Cephas Dzogbewu, Deon Johan de Beer   +2 more
wiley   +1 more source

Impact of residual tricuspid regurgitation after transcatheter tricuspid therapies on right and left ventricular mechanics: insights from a case series. [PDF]

Eur Heart J Case Rep
Mondellini GM, van den Enden AJM, van den Dorpel MMP, Meuwese CL, Van Mieghem NM.   +4 more
europepmc   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (ADME) of inhaled londamocitinib ...
Camille Riff, Peter Bold, Maria Heijer, Ryan A. Bragg, Danielle Steele, Tina Jellesmark Jensen, Davinder P. S. Dosanjh, Sabrina I. Hanswijk‐Bartelds, Esther van Duijn, Elwin R. Verheij, Somasekhara Menakuru, Rod Hughes, Helena Dahlbäck   +12 more
wiley   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

British Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu, Amina Haggag, Laurie Butcher, Haihui Liu, Wen Chen, Xuefeng Sun, Aruni Jha, Hongtao Yu, Anis Khan, Victoria E. R. Parker, Christer Tannergren, Xiaoliang Pan, Jianfeng Xu, Jingye Zhou   +13 more
wiley   +1 more source

82148 | Ventricular and Atrial Strain Analysis After M-TEER: A Retrospective Single Center Study

Structural Heart
Georgios Papadopoulos, Ilias Ninios, Sotirios Evangelou, Andreas Ioannides, Vlasis Ninios   +4 more
openaire   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

British Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C. Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee‐Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C. Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J. Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner   +24 more
wiley   +1 more source

M-TEER for Progressive MR Following TTVR in Combined Atrioventricular Valve Regurgitation Due to Biatrial Dilation

JACC: Cardiovascular Interventions
Alexander Hof, Marcel Halbach, Dennis Mehrkens, Matti Adam, Maria Isabel Körber, Stephan Baldus, Roman Pfister, Christos Iliadis   +7 more
openaire   +2 more sources